Retinoblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026
- Transparency Market Research
- December 2039
- 0 pages
Retina is the third-inner layer of the eye, responsible for light and color detection. Retinoblastoma is a rare type of cancer which develops in the retina, particularly in children. Exact causes of retinoblastoma are not known; however, literature suggests that family history with retinoblastoma is the key reason for transmission of this disorder to the offspring. Retinoblastoma generally develops in one eye of the children; however, in certain cases, both the eyes can be affected. Symptoms of retinoblastoma are leukocoria (whiteness in the pupil), strabismus (crossed eyes), redness, color blindness, and poor vision. Retinoblastoma can be cured if treated at the first stage. Improper treatment can cause blindness and, sometimes, death. For diagnosis of retinoblastoma, imaging tests such as ultrasound, CT-scan, MRI, X-ray, bone scan (to check whether retinoblastoma has spread to the bone of the skull) are available. Taking a tissue from the eye for biopsy examination is risky for the patients; therefore, biopsy examination for retinoblastoma is generally avoided. Apart from surgery, certain drugs are available in the market which can cure retinoblastoma.
The retinoblastoma treatment market is expected to be driven by the increasing number of cases with retinoblastoma, diagnosis and treatment rate of retinoblastoma, regional healthcare expenditure for ophthalmic treatment, and healthcare infrastructure. However, lack of awareness about retinoblastoma, inadequate availability of retinoblastoma treatment drugs, stringent regional regulatory landscape, and intellectual property rights are anticipated to restrain the global retinoblastoma treatment market. Nonetheless, increasing R&D investment and the ongoing research on ophthalmology are the opportunities for the global retinoblastoma treatment market to grow during the forecast period.
In terms of drugs, the retinoblastoma treatment market can be segmented into single drugs and combinatory drugs. By types, the retinoblastoma treatment market can be categorized into unilateral retinoblastoma, bilateral retinoblastoma, and neuro-ectodermal tumors retinoblastoma. Based on delivery of drugs, the retinoblastoma treatment market can be classified into intravitreal, intra-arterial, peiocular, and others. In terms of end-user, the retinoblastoma treatment market can be divided into hospitals, independent eye clinics, and others.
Geographically, the global retinoblastoma treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to the American Cancer Society, around 200-300 children are affected with retinoblastoma every year in the U.S. It also documented that 3 out 4 children have retinoblastoma in one eye and 1 out of 4 children are affected with retinoblastoma in both the eyes. Between 2009 and 2013, around 130 children (between 0 to 14 years of age) were diagnosed with retinoblastoma and 3 children lost their lives due to this cancer in Canada, as revealed by the Canadian Cancer Society. On the other hand, around 300 new cases per year with retinoblastoma affected are found in Europe in 2016, which reflects the scenario of the U.S. North America and Europe held major shares of the retinoblastoma treatment market in 2016 and are projected to exhibit significant growth rates during the forecast period, owing to the increasing incidence of retinoblastoma in the regions, high diagnosis and treatment rate of retinoblastoma, strong medical infrastructure, and impressive healthcare expenditure for ophthalmic treatment. The retinoblastoma treatment market in Asia Pacific is estimated to witness the third highest market share in 2016. It is expected to expand at a significantly high rate during the forecast period due to the large patient pool in Asia Pacific, developing healthcare infrastructure, availability of generic drugs, and presence of local players in the market. Low diagnosis and treatment rate of retinoblastoma and inadequate medical infrastructure are anticipated to restrain the growth of the retinoblastoma treatment market in Latin America and Middle East & Africa during the forecast period.
Key players in the global retinoblastoma treatment market include Baxter Healthcare Corporation, AMERIGEN PHARMS LTD, West-Ward Pharmaceuticals Corp, Hospira (parent organization Pfizer), and Teva Pharmaceuticals Industries.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017